drugset / Trial / NCT03952481
Effect of Lifitegrast 5% on Tear Film Markers
NaSingle-groupOpen-labelDiagnostic
Summary
The purpose of this study is to assess the duration of time (in weeks) for improvement in objective dry eye markers for people who are placed on lifitegrast 0.5% (Xiidra®), an FDA-approved therapy for dry eyes.
Timeline
- Start
- 2021-03-01
- Primary completion
- 2021-12-31
- Completion
- 2021-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lifitegrast | Unknown | 5 % | Other |